Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Q2 FY2027 Earnings Presentation
34 slides from Cohance Lifesciences's earnings presentation, Nov 6, 2026
Slide 1: Cover letter to BSE and NSE
6 November 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400001 Bandra (E), Mumbai – 400051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Investor Presentation Please find annexed
Slide 2: Investor Presentation Q2 FY2027
INVESTOR PRESENTATION Q2 FY2027 November 2026
Slide 3: Disclaimer
Disclaimer This document and information herein is solely for information purposes and must not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. This document may not be altered in any way, transmitted to,
Slide 4: Table of Contents
Table of Contents Executive Business and Awards & Business wise Annexure summary Financial Recognition Strategy performance and ESG 04 06 15 19 30 3
Slide 5: Executive Summary
Cohance Executive Summary
Slide 6: Executive Summary – Q2FY27 and H1FY27
Executive Summary Executive Summary – Q2FY27 and H1FY27 Q2FY27: Sequential recovery gaining traction; integrated capabilities strengthening the growth platform Q2 delivered a clear sequential recovery, with revenue up ~13% QoQ and adjusted EBITDA margin improving to 10% from 2% in Q1, demonstratin
Slide 7: Business and Financial Performance
Business and Financial Performance 6
Slide 8: Q2FY27: Q2 Delivered Sequential Growth
BUSINESS AND FINANCIAL PERFORMANCE Q2FY27: Q2 Delivered Sequential Growth Q2FY27 performance: Q2FY27 Financial Highlights____________________________ Q2FY27 revenue declined 14.2% YoY to INR 4,766 Mn, due to lower Pharma CDMO and AgChem contributions and an unfavourable business and product mix. Q
Slide 9: Q2FY27 Consolidated Financial Results
BUSINESS AND FINANCIAL PERFORMANCE Q2FY27 Consolidated Financial Results INR Mn Particulars Q2FY27 Q1FY27 Q2FY26 QoQ YoY • In Q2, CDMO (Pharma CDMO + Specialty Chemicals) share Revenue from Operations 4,766 4,223 5,556 12.9% -14.2% Material costs / COGS (1,391) (1,203) (1,412) was 44%, only API+ bus
Slide 10: H1FY27 Consolidated Financial Results
BUSINESS AND FINANCIAL PERFORMANCE H1FY27 Consolidated Financial Results INR Mn Particulars 1HFY27 1HFY26 YoY • In H1FY27, CDMO (Pharma CDMO + Specialty Chemicals) Revenue from Operations 8,989 11,049 -18.6% Material costs / COGS (2,594) (2,893) share was 41%, all the business segments witnessed Mat
Slide 11: Q2FY27 – Business Performance Overview
BUSINESS AND FINANCIAL PERFORMANCE Q2FY27 –Business Performance Overview Consolidated Financials Operational Revenue (INR Mn) Adjusted EBITDA (INR Mn) Margin (%) Adjusted PAT (INR Mn) 23.2% 709 5,556 -14.2% 4,766 9.6% 74 1,288 459 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Pharma CDMO (INR Mn) Spec
Slide 12: H1FY27 – Business Performance Overview
BUSINESS AND FINANCIAL PERFORMANCE H1FY27 –Business Performance Overview Consolidated Financials Operational Revenue (INR Mn) Adjusted EBITDA (INR Mn) Margin (%) Adjusted PAT (INR Mn) 11,049 23.8% 1,301 -18.6% 8,989 6.1% 2,629 551 (355) 1HFY26 1HFY27 1HFY26 1HFY27 1HFY26 1HFY27 Pharma CDMO (INR Mn
Slide 13: Balance Sheet H1FY27
BUSINESS AND FINANCIAL PERFORMANCE Balance Sheet H1FY27 INR Mn Balance Sheet Snapshot1 FY25 FY26 1HFY27 Property, plant and equipment (PPE) 15,583 17,907 17,511 Right of use asset (RoU) 2,418 2,311 2,161 Capital work-in-progress 3,316 1,732 2,158 • The balance sheet remains resilient and net cash po
Slide 14: Financial Ratios 1HFY27
BUSINESS AND FINANCIAL PERFORMANCE Financial Ratios 1HFY27 Key Ratios(Adjusted)# FY25 FY26 1HFY27 Basis Net Working Capital (as days of sales) 136 154 148 NWC / Revenue * 365 days PPE (as % of sales) 57.2% 81.7% 81.9% PPE / Revenue Capex spend during the year/period (INR Mn) 3,147 2,154 1,077 Capex
Slide 15: Awards & Recognition and ESG
Awards & Recognition and ESG 14
Slide 16: Awards
AWARDS & RECOGNITION AND ESG Awards Recognition for excellence in ADC CRO services NJ Bio, Inc. was named Runner-Up in the Best Contract Research Organization (CRO) category at the 2026 World ADC Awards, marking seven consecutive years of recognition 15
Slide 17: Achievements
AWARDS & RECOGNITION AND ESG Achievements Independent recognition of Cohance's Science-Based Targets: SBTi Validation safety culture and sustainability Near-term and net-zero emissions targets formally performance validated by SBTi Services EcoVadis Gold Rating and CDP rating NEAR-TERM — FY2035 Coha
Slide 18: ESG Aspirations
AWARDS & RECOGNITION AND ESG ESG Aspirations We have set multi-dimensional ESG goals Our achievement Environment Social Governance Upcoming milestones Achieved B rating in Climate Retention of Eco Vadis Gold Change and A- Water in 2025 Reduce absolute Scope 1,2 Employees undergo Ethical non- in Sust
Slide 19: Sustainability Progress
AWARDS & RECOGNITION AND ESG Sustainability Progress Completed projects, assessments and management systems Environmental projects External assessments & disclosures ANK: SURJA-II solar plant Group captive model 61 - Overall ESG 7 MWp 54 - ESG Score 10.85m kWh/year renewable power 67 - Core ESG ~7,7
Slide 20: Business Wise Strategy
Business Wise Strategy 19
Slide 21: Our Growth Engines – Pharma CDMO Key Driver
BUSINESS WISE STRATEGY Our Growth Engines – Pharma CDMO Key Driver 42% Specialty 8% 50% Pharma CDMO* API+* of Sales Chemicals* of Sales of Sales Small Molecules ADC* Payload –linker – Thrust on adding anchor relationships and Expanding selectively into adjacent, 18 Commercial Patented Bioconju
Slide 22: Pharma CDMO
Pharma CDMO 21
Slide 23: Medium to Long Term Strategic Approach
PHARMA CDMO Medium to Long Term Strategic Approach Our 30+ year relationships with global innovators and proven expertise in scaling up hazardous chemistry, complex chiral and multi step synthesis offer us a significant and unique advantage. Customer Centricity and Readiness: o Customer at the core
Slide 24: Pharma CDMO: Advancement across programmes
PHARMA CDMO Pharma CDMO: Advancement across programmes Small Molecules Phase III pipeline Improved H2 visibility: Stronger Q3/Q4 order book and improved commercial reload visibility Phase III molecules Phase III intermediate are expected to support sequential recovery in the second half 10 Stron
Slide 25: ADC and OLIGOS: Maintain strong outlook
PHARMA CDMO ADC and OLIGOS: Maintain strong outlook ADC Market Size ($ Bn) Customer Increasing RFQ NJ Bio NJ Bio Bioconjugation destocking activity across reorganisation successfully capacity US$68.0bn CAGR impacted H1 payloads and strengthens delivered two expansion on Market to 14.8%+ performance,
Slide 26: Creating One Integrated Nucleic Acid business
NUCLEIC ACID BUSINESS (erstwhile Sapala Organics) Creating One Integrated Nucleic Acid business Strong Manufacturing Focus on growth opportunities expansion Nucleic Acid Business (Sapala) Integration progressing through Focus on expanding continues to deliver strong coordinated commercial capabiliti
Slide 27: API+
Cohance API+
Slide 28: API+: Resilient performance
API+ API+: Resilient performance API+ continued to deliver resilient YoY revenue growth, supported by a healthy order book and selective pricing actions, despite lower volumes and raw-material cost pressures Strategic focus remains on niche APIs, controlled substances and innovator lifecycle-man
Slide 29: Specialty Chemicals
Cohance Specialty Chemicals
Slide 30: SPEC/Ag CHEM: Tepid performance amidst pricing pressure
SPECIALTY CHEMICALS SPEC/Ag CHEM: Tepid performance amidst pricing pressure Specialty Chemicals — AgChem AgChem Strategic focus on Qualification Opportunities performance broadening the programmes emerging from impacted by lower innovator-led progressing with supply-chain volumes, pricing portfolio
Slide 31: Annexures
Annexures 30
Slide 32: R&D and Manufacturing Facilities
ANNEXURES R&D and Manufacturing Facilities Lab & Kilo scale Pilot and Commercial scale (~3,000+ kL capacity) Pharma CDMO Genome valley, Nacharam, Hyderabad Princeton, Suryapet, Pashamylaram, Vizag, Nacharam, Jeedimetla, Hyderabad Hyderabad (Oligo CoE) New Jersey Telangana Hyderabad Andhra Pradesh Hy
Slide 33: Contact Information
ANNEXURES Contact Information Cyndrella Carvalho, Head - Investor Relations Gavin Desa, Konpal Pali Cohance Lifesciences Ltd CDR - India Email: [email protected] Tel: +91 98206 37649; +91 76619 08341 Email: [email protected]; [email protected] 32
Slide 34: Thank You
Thank You
Cohance Lifesciences — Q2 FY2027 Earnings Presentation on 6ix